Cybin (CYBN) announced that the company will operate under the business name Helus Pharma and trade on Nasdaq with ticker symbol (HELP). The company has transferred its U.S. stock exchange listing from the NYSE American to the Nasdaq. The company will continue to be listed on the Cboe Canada and will trade under the same ticker symbol. The company expects to seek approval from shareholders to change its legal name to Helus Pharma at the company’s next annual and special meeting of shareholders.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Launches US$100 Million At-the-Market Equity Program
- Cybin Sets Up US$100 Million At-the-Market Equity Program With Cantor Fitzgerald
- Cybin initiates at-the-market equity program of up to $100M
- Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January
- Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq